Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-23-128874
Filing Date
2023-05-01
Accepted
2023-05-01 08:31:01
Documents
15
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A d213578d10ka.htm   iXBRL 10-K/A 353870
2 EX-31.2 d213578dex312.htm EX-31.2 3538
  Complete submission text file 0001193125-23-128874.txt   637410

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mgta-20221231.xsd EX-101.SCH 4974
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE mgta-20221231_cal.xml EX-101.CAL 673
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mgta-20221231_def.xml EX-101.DEF 19850
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE mgta-20221231_lab.xml EX-101.LAB 26591
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mgta-20221231_pre.xml EX-101.PRE 21322
9 EXTRACTED XBRL INSTANCE DOCUMENT d213578d10ka_htm.xml XML 9846
Mailing Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139
Business Address 300 TECHNOLOGY SQUARE 8TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Magenta Therapeutics, Inc. (Filer) CIK: 0001690585 (see all company filings)

EIN.: 000000000 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38541 | Film No.: 23870332
SIC: 2834 Pharmaceutical Preparations